drugset / Trial / NCT06384482
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Phase 1
Unknown
35 enrolled
Shanghai Simnova Biotechnology Co.,Ltd.
Shanghai Chest Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma.
Timeline
- Start
- 2024-04-30
- Primary completion
- 2025-04-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNC115 | Cell therapy | — | — |